June 2016 CFTN
An AACC/CAP Educational Newsletter for Toxicology Laboratories
CFTN is registered with the U.S. Library of Congress, ISSN 2374-9679.
Read the June 2016 issue of CFTN
Welcome to CFTN for June 2016. Clinical & Forensic Toxicology News for June, 2016 is now available online. Articles in this issue are centered on adulteration and additives to drugs as well as herbal medicine. Send us feedback and let us know what you think.
Suggested citation for CFTN
Author’s last name(s), first and middle initials. (Date of Publication). Title of article. Clinical and Forensic Toxicology News (Quarterly, AACC/CAP), pages. Available from [specific web URL of posting].
Ritchie J (March 2016). Kratom: Herb Gains Popularity as a Gentler Opiate Substitute. Clinical and Forensic Toxicology News (Quarterly, AACC/CAP), 8-10. Available from https://www.aacc.org/publications/clinical-and-forensic-toxicology-news
Designer Drugs Keep Evolving
Novel Psychoactive Substances Challenge Laboratories and Laws
By Sherri L. Kacinko, PhD, and Donna Papsun, MS
Designer drugs, research chemicals, novel psychoactive substances (NPS), and legal highs are all terms used to describe drugs designed to skirt legal controls. Although the trend toward using these drugs picked up steam in the new millennium, the search for new recreational substances— either through repurposing pharmaceutical research or modifying existing drugs of abuse—is not new.
Testing for Everolimus
Immunoassays Make Advances,But LC-MS/MS Is Still Preferred
By Kamisha L. Johnson-Davis, PhD, DABCC, FACB
Everolimus is an immunosuppressant drug for prophylaxis of acute and chronic rejection in patients who receive renal or cardiac transplants. It is sold under the brand names Certican, Zortress, and Afinitor.
Many AACC Meeting Sessions
Cover Toxicology and TDM Topics
By Christine Snozek, PhD, DABCC, FACB
It’s that time of year again—the AACC 2016 annual meeting will be held in Philadelphia from July 31 to August 4. There is a great lineup of speakers related to therapeutic drug monitoring and toxicology, including Thursday’s plenary speaker, Dr. Marilyn Huestis, chief of the chemistry and drug metabolism section in the intramural research program at the National Institute on Drug Abuse. Dr. Huestis will be addressing laboratory and societal concerns related to medical marijuana.